Table 4.
Cytology (≥HSIL), High-Risk HPV, and TERC Amplification Analyses in Association with Different Age Groups for the Detection of High-Grade Cervical Lesions and Invasive Cancer (n = 2316)
| Cytology |
High-risk HPV |
TERC |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | 18–29 | 30–49 | 50–64 | 65+ | 18–29 | 30–49 | 50–64 | 65+ | 18–29 | 30–49 | 50–64 | 65+ |
| Sensitivity, % (95%CI) | 38.2 (66.5–81.6) | 56.3 (53.0–59.6) | 54.1 (45.3–62.9) | 50.0 (23.8–76.2) | 91.6 (86.9–96.4) | 91.5 (89.6–93.3) | 91.0 (85.9–96.1) | 78.6 (57.1–100.0) | 74.0 (66.5–81.6) | 81.6 (79.0–84.2) | 82.0 (75.1–88.8) | 78.6 (57.1–100.0) |
| Specificity, % (95%CI) | 95.5 (92.8–98.2) | 93.0 (91.2–94.7) | 92.2 (87.8–96.6) | 85.7 (59.8–100.0) | 29.7 (23.7–35.7) | 41.3 (37.9–44.7) | 43.3 (35.1–51.4) | 28.6 (0–62.0) | 88.7 (84.6–92.9) | 82.1 (79.4–84.7) | 85.8 (80.1–91.6) | 85.7 (59.8–100.0) |
| PPV, % (95%CI) | 83.3 (73.9–92.8) | 89.6 (87.0–92.1) | 85.7 (77.9–93.5) | 87.5 (64.6–100.0) | 43.5 (37.6–49.3) | 62.6 (60.0–65.3) | 58.1 (51.1–65.1) | 68.8 (46.0–91.5) | 79.5 (72.3–86.7) | 83.0 (80.5–85.6) | 83.3 (76.7–90.0) | 91.7 (76.0–100.0) |
| NPV, % (95%CI) | 72.4 (67.2–77.5) | 66.4 (63.7–69.2) | 69.9 (63.3–76.5) | 46.2 (19.1–73.3) | 85.7 (77.9–93.5) | 81.9 (78.1–85.6) | 84.7 (76.4–93.0) | 40.0 (0–82.9) | 85.3 (80.7–89.9) | 80.6 (77.9–83.3) | 84.6 (78.7–90.5) | 66.7 (35.9–97.5) |
| Youden's index, % (95%CI) | 33.7 (24.9–42.4) | 49.3 (45.5–53.0) | 46.3 (36.4–56.2) | 35.7 (0–72.6) | 21.3 (13.7–29.0) | 32.8 (28.9–36.6) | 34.2 (24.6–43.9) | 7.1 (0–46.9) | 62.8 (54.2–71.4) | 63.7 (60.0–67.4) | 67.8 (58.9–76.7) | 64.3 (30.6–98.0) |